Psilocybin for Treatment-Resistant Depression

Søren D. Østergaard; Fredrik Hieronymus; Bruno Roméo; Alain Dervaux; Amine Benyamina; Aiste Lengvenyte; Emilie Olié; Philippe Courtet; Guy M. Goodwin; David J. Hellerstein; Allan H. Young

doi:10.1056/NEJMc2215459

Psilocybin for Treatment-Resistant Depression

Søren D. Østergaard, Fredrik Hieronymus, Bruno Roméo, Alain Dervaux, Amine Benyamina, Aiste Lengvenyte, Emilie Olié, Philippe Courtet, Guy M. Goodwin, David J. Hellerstein, Allan H. Young

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	1637-1648
Number of pages	12
Journal	New England Journal of Medicine
Volume	388
Issue number	8
DOIs	https://doi.org/10.1056/NEJMc2215459
Publication status	Published - 1 Nov 2023

Access to Document

10.1056/NEJMc2215459

Cite this

@article{c341a914717e46208a17bd294991ff19,

title = "Psilocybin for Treatment-Resistant Depression",

author = "{\O}stergaard, {S{\o}ren D.} and Fredrik Hieronymus and Bruno Rom{\'e}o and Alain Dervaux and Amine Benyamina and Aiste Lengvenyte and Emilie Oli{\'e} and Philippe Courtet and Goodwin, {Guy M.} and Hellerstein, {David J.} and Young, {Allan H.}",

note = "Funding Information: Dr. {\O}stergaard reports receiving grants from the Lundbeck Foundation, receiving the 2020 Lundbeck Foundation Young Investigator Prize, owning or having owned units of mutual funds with stock tickers DKIGI, IAIMWC, SPIC25KL, and WEKAFKI and having owned units of exchange traded funds with stock tickers 2B76, BATE, EUNL, EXH2, IQQH, QDV5, QDVE, QDVH, SADM, TRET, and USPY. Dr. Hieronymus reports receiving a grant from the Lundbeck Foundation and speaker{\textquoteright}s fees from H. Lundbeck and Janssen. No other potential conflict of interest relevant to this letter was reported. ",

year = "2023",

month = nov,

day = "1",

doi = "10.1056/NEJMc2215459",

language = "English",

volume = "388",

pages = "1637--1648",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "8",

}

TY - JOUR

T1 - Psilocybin for Treatment-Resistant Depression

AU - Østergaard, Søren D.

AU - Hieronymus, Fredrik

AU - Roméo, Bruno

AU - Dervaux, Alain

AU - Benyamina, Amine

AU - Lengvenyte, Aiste

AU - Olié, Emilie

AU - Courtet, Philippe

AU - Goodwin, Guy M.

AU - Hellerstein, David J.

AU - Young, Allan H.

N1 - Funding Information: Dr. Østergaard reports receiving grants from the Lundbeck Foundation, receiving the 2020 Lundbeck Foundation Young Investigator Prize, owning or having owned units of mutual funds with stock tickers DKIGI, IAIMWC, SPIC25KL, and WEKAFKI and having owned units of exchange traded funds with stock tickers 2B76, BATE, EUNL, EXH2, IQQH, QDV5, QDVE, QDVH, SADM, TRET, and USPY. Dr. Hieronymus reports receiving a grant from the Lundbeck Foundation and speaker’s fees from H. Lundbeck and Janssen. No other potential conflict of interest relevant to this letter was reported.

PY - 2023/11/1

Y1 - 2023/11/1

UR - http://www.scopus.com/inward/record.url?scp=85148550537&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2215459

DO - 10.1056/NEJMc2215459

M3 - Letter

C2 - 36812443

AN - SCOPUS:85148550537

SN - 0028-4793

VL - 388

SP - 1637

EP - 1648

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 8

ER -

Psilocybin for Treatment-Resistant Depression

Access to Document

Other files and links

Cite this